Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Discharge Via an Intermediate Care Unit

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT01706744
First received: October 11, 2012
Last updated: November 21, 2014
Last verified: November 2014
  Purpose

The main goal is to investigate the following topics:

  1. Can discharge via the Intermediate Care Unit in Stjørdal, compared to direct discharge to Verdal Municipality, be equally effective in preventing aggravation of disease and loss of function for patients over 60 years that have been hospitalized in Levanger hospital?
  2. Are the cost by discharge to the Intermediate Care Unit in Stjørdal, when the hospital is not located in the same Municipality, comparable to the cost by direct discharge to the Municipality of Verdal, for patients over 60 years that have been hospitalized in Levanger hospital?
  3. Which issues are considered important by patients and health personnel during discharge, arrival and follow up in the Municipality, to ensure an optimal interaction between the involved units.

Condition Intervention
Patients
Aged
Other: Intermediate care unit
Other: Local health care 1
Other: Local health care 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Can Discharge Via an Intermediate Care Unit Prevent Aggravation of Disease and Loss of Functionality, Without Increasing the Level of Cost? A Controlled Observational Study

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Hospital readmission [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Acute admission to hospital within 30 days from previous discharge

  • Use of local health care services [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • death [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
  • hospital admission [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
  • functional assessment status [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
  • Health service cost [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]

Enrollment: 328
Study Start Date: February 2010
Study Completion Date: October 2013
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intermediate care unit
Follow-up treatment and care in a intermediate care unit after discharge from hospital
Other: Intermediate care unit
Active Comparator: Local health care 1
Discharge from hospital to usual care as provided by the local health and social care (Verdal)
Other: Local health care 1
Active Comparator: Local health care 2
Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
Other: Local health care 2

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients 60 years old or older from Stjørdal- or Verdal municipality,

  • given consent,
  • admitted from their home,
  • diagnostics completed and necessary treatment started
  • the patient need not less than 3-4 days institutionalization for treatment/rehabilitation/care

Exclusion Criteria:

  • Patients with severe dementia
  • Patients with severe disease who cannot give consent
  • Patients with severe disease with short life expectancy (including severe cancer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01706744

Locations
Norway
Sykehuset Levanger
Levanger, Norway
Distriksmedisinsk Senter
Stjørdal, Norway
Stjørdal Kommune
Stjørdal, Norway
Verdal kommune
Verdal, Norway
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Study Director: Roar Johnsen, PhD Norwegian University of Science and Technology
  More Information

No publications provided

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT01706744     History of Changes
Other Study ID Numbers: 2009/1697
Study First Received: October 11, 2012
Last Updated: November 21, 2014
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Keywords provided by Norwegian University of Science and Technology:
Hospital Readmissions
Community Health Services
Preventive Health Services
Norway

ClinicalTrials.gov processed this record on November 24, 2014